SCHEMBL24253712

SCHEMBL24253712

O=C1CCCC2(CCN(c3nccc(C(F)(F)F)n3)CC2)N1c1ccc(Cl)c(F)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.41
ADRB1 P08588 1/20 0.41
KDM4E B2RXH2 2/20 0.39
PKM P14618 2/20 0.38
NR1H3 Q13133 6/20 0.37
NR1H2 P55055 5/20 0.36
RBP4 P02753 1/20 0.36
SLC6A7 Q99884 1/20 0.36
OGA O60502 1/20 0.35
LCAT P04180 1/20 0.34
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA9 Q16790 1/20 0.34
SLC6A2 P23975 1/20 0.34
SLC6A3 Q01959 1/20 0.34
AOC3 Q16853 1/20 0.33
HCRTR1 O43613 1/20 0.33
HCRTR2 O43614 1/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30423539 1.00 KMT2A (0.41) KMT2AADRB1KDM4EPKMNR1H3
SCHEMBL24253827 0.84 AOC3 (0.33) AOC3HCRTR1HCRTR2
SCHEMBL30424094 0.84 AOC3 (0.33) AOC3HCRTR1HCRTR2
SCHEMBL30423561 0.84 DPP4 (0.36) AOC3HCRTR1HCRTR2ALDH1A1
SCHEMBL24253726 0.84 DPP4 (0.36) AOC3HCRTR1HCRTR2ALDH1A1
SCHEMBL24253828 0.82 HCRTR1 (0.33) AOC3HCRTR1HCRTR2ALDH1A1
SCHEMBL30423960 0.82 HCRTR1 (0.33) AOC3HCRTR1HCRTR2ALDH1A1
SCHEMBL24253843 0.82 AOC3 (0.34) KMT2AAOC3HCRTR1HCRTR2ALDH1A1
SCHEMBL30424819 0.82 AOC3 (0.34) KMT2AAOC3HCRTR1HCRTR2ALDH1A1
SCHEMBL30423990 0.81 CYP11B2 (0.35) AOC3HCRTR1HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof NOVARTIS AG (CH) 2023-07-25 US disclosed
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof NOVARTIS AG (CH) 2023-07-25 US disclosed
US-20220048909-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof REN, NR3C2, PKD1 KMT2A 3399/4885ADRB1 20/4885KDM4E 2714/4885
US-20220048909-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF REN, NR3C2, PKD1 KMT2A 3399/4885ADRB1 20/4885KDM4E 2714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.